Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions.
Michael SeoThomas P A DebrayYann RuffieuxSandro GsteigerSylwia BujkiewiczAxel FinckhMatthias EggerOrestis EfthimiouPublished in: Statistical methods in medical research (2022)
Meta-analysis of randomized controlled trials is generally considered the most reliable source of estimates of relative treatment effects. However, in the last few years, there has been interest in using non-randomized studies to complement evidence from randomized controlled trials. Several meta-analytical models have been proposed to this end. Such models mainly focussed on estimating the average relative effects of interventions. In real-life clinical practice, when deciding on how to treat a patient, it might be of great interest to have personalized predictions of absolute outcomes under several available treatment options. This paper describes a general framework for developing models that combine individual patient data from randomized controlled trials and non-randomized study when aiming to predict outcomes for a set of competing medical interventions applied in real-world clinical settings. We also discuss methods for measuring the models' performance to identify the optimal model to use in each setting. We focus on the case of continuous outcomes and illustrate our methods using a data set from rheumatoid arthritis, comprising patient-level data from three randomized controlled trials and two registries from Switzerland and Britain.
Keyphrases
- randomized controlled trial
- case report
- electronic health record
- rheumatoid arthritis
- double blind
- open label
- placebo controlled
- big data
- clinical practice
- physical activity
- phase iii
- healthcare
- phase ii
- clinical trial
- type diabetes
- machine learning
- study protocol
- metabolic syndrome
- adipose tissue
- systemic sclerosis
- skeletal muscle
- systemic lupus erythematosus
- disease activity
- ankylosing spondylitis
- weight loss